Pancreatic Carcinoma: Exploring its Relationship with Diabetes and the Potential Chemopreventive Effects of Metformin

Authors

  • Divya Mahajan Senior Resident, Department of Radiation Oncology, Goverment Medical College and Hospital Sector 32 Chandigarh, India.
  • Awadesh kumar Pandey Head of Department, Department of Radiation Oncology, Goverment Medical College and Hospitalsector 32 Chandigarh, India.

DOI:

https://doi.org/10.31557/apjcb.2024.9.1.61-66

Keywords:

pancreas cancer, diabetes mellitus, metformin

Abstract

Background: Pancreatic cancer and type 2 diabetes mellitus have been found to be interrelated, with emerging evidence suggesting that metformin may have a chemoprotective role in reducing the risk of pancreatic cancer in patients with diabetes.

Methods: A comprehensive systematic search was conducted across databases, including PubMed, Web of Science, and the Cochrane Library. The search terms included "metformin," "biguanide," "pancreatic cancer," "pancreatic tumor," and "diabetes mellitus" in the title and abstract fields.

Results: A meta-analysis of 18 studies using a random-effects model showed that metformin use was associated with a reduced risk of pancreatic cancer in patients with type 2 diabetes, compared to those who did not use metformin.

Conclusion: This review highlights the chemoprotective effect of metformin in reducing the risk of pancreatic cancer among diabetic patients. Further research is needed to explore the mechanisms behind this association and to confirm these findings.

Downloads

Published

2024-01-09

How to Cite

1.
Mahajan D, Pandey A kumar. Pancreatic Carcinoma: Exploring its Relationship with Diabetes and the Potential Chemopreventive Effects of Metformin. Asian Pac J Cancer Biol [Internet]. 2024 Jan. 9 [cited 2026 Jun. 4];9(1):61-6. Available from: http://waocp.com/journal/index.php/apjcb/article/view/1203

Issue

Vol. 9 No. 1 (2024)

Section

Systematic Review and Meta-analysis:

License

 West Asia Organization for Cabcer Prevention retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4 (This permits anyone to copy, distribute, transmit and adapt the published work, provided the original work and source are appropriately cited).